JP2003506491A - 細胞接着インヒビター - Google Patents

細胞接着インヒビター

Info

Publication number
JP2003506491A
JP2003506491A JP2001516532A JP2001516532A JP2003506491A JP 2003506491 A JP2003506491 A JP 2003506491A JP 2001516532 A JP2001516532 A JP 2001516532A JP 2001516532 A JP2001516532 A JP 2001516532A JP 2003506491 A JP2003506491 A JP 2003506491A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
alkenyl
substituted
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001516532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003506491A5 (enExample
Inventor
ウェン−チャーン リー，
ダニエル スコット，
マーク コーンバイス，
ラッセル ピーター，
Original Assignee
バイオジェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオジェン インコーポレイテッド filed Critical バイオジェン インコーポレイテッド
Publication of JP2003506491A publication Critical patent/JP2003506491A/ja
Publication of JP2003506491A5 publication Critical patent/JP2003506491A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
JP2001516532A 1999-08-13 2000-08-14 細胞接着インヒビター Pending JP2003506491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14884599P 1999-08-13 1999-08-13
US60/148,845 1999-08-13
PCT/US2000/022285 WO2001012186A1 (en) 1999-08-13 2000-08-14 Cell adhesion inhibitors

Publications (2)

Publication Number Publication Date
JP2003506491A true JP2003506491A (ja) 2003-02-18
JP2003506491A5 JP2003506491A5 (enExample) 2005-10-27

Family

ID=22527673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001516532A Pending JP2003506491A (ja) 1999-08-13 2000-08-14 細胞接着インヒビター

Country Status (31)

Country Link
US (3) US6630503B1 (enExample)
EP (2) EP1741428A3 (enExample)
JP (1) JP2003506491A (enExample)
KR (1) KR100720907B1 (enExample)
CN (1) CN1377268A (enExample)
AT (1) ATE343383T1 (enExample)
AU (1) AU780610B2 (enExample)
BG (1) BG65755B1 (enExample)
BR (1) BR0013248A (enExample)
CA (1) CA2380817A1 (enExample)
CY (1) CY1105912T1 (enExample)
CZ (1) CZ2002518A3 (enExample)
DE (1) DE60031577T2 (enExample)
DK (1) DK1265606T3 (enExample)
EA (1) EA005578B1 (enExample)
EE (1) EE200200070A (enExample)
ES (1) ES2270868T3 (enExample)
GE (2) GEP20063956B (enExample)
HU (1) HUP0202469A3 (enExample)
IL (2) IL148014A0 (enExample)
IS (1) IS6257A (enExample)
MX (1) MXPA02001449A (enExample)
NO (1) NO324044B1 (enExample)
NZ (1) NZ517011A (enExample)
PL (1) PL354063A1 (enExample)
PT (1) PT1265606E (enExample)
RS (1) RS50470B (enExample)
SK (1) SK287075B6 (enExample)
UA (1) UA75581C2 (enExample)
WO (1) WO2001012186A1 (enExample)
ZA (1) ZA200201158B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002201168A (ja) * 2000-12-28 2002-07-16 Kaken Pharmaceut Co Ltd シクロヘキサン誘導体
JP2007518825A (ja) * 2004-01-23 2007-07-12 イーラン ファーマスーティカルズ、インコーポレイテッド 複素環式アルキルカルボキサミドプロパノン酸類のポリエチレングリコール抱合体類
JP2008505927A (ja) * 2004-07-08 2008-02-28 イーラン ファーマスーティカルズ、インコーポレイテッド ポリマー部分を含む多価ｖｌａ−４拮抗薬

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ES2270868T3 (es) * 1999-08-13 2007-04-16 Biogen Idec Ma Inc. Inhibidores de la adhesion celular.
DE10006453A1 (de) * 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
CA2430978C (en) 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
JP2004526733A (ja) * 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド 強力な細胞接着阻害剤としての置換ｎ−アリールスルホニル−プロリン誘導体
US6663489B2 (en) 2001-08-24 2003-12-16 Igt Gaming device having an award distributor and an award accumulator bonus game
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
JP4676884B2 (ja) 2003-07-24 2011-04-27 第一三共株式会社 シクロヘキサンカルボン酸類
US7196112B2 (en) * 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
EP2623113B1 (en) * 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
JP2009545620A (ja) * 2006-08-02 2009-12-24 ジェンザイム・コーポレーション 併用療法
TW200817319A (en) 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2016179343A1 (en) 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
US10836720B2 (en) 2016-04-01 2020-11-17 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
CN109721605B (zh) * 2017-10-31 2022-03-11 维眸生物科技（上海）有限公司 一种免疫细胞迁徙抑制剂
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003094A1 (en) * 1995-07-11 1997-01-30 Biogen, Inc. Cell adhesion inhibitors
WO1997023480A1 (en) * 1995-12-22 1997-07-03 The Du Pont Merck Pharmaceutical Company Novel integrin receptor antagonists
WO1997048395A1 (en) * 1996-06-19 1997-12-24 Du Pont Pharmaceuticals Company Iontophoretic delivery of integrin inhibitors
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
WO1998058902A1 (en) * 1997-06-23 1998-12-30 Tanabe Seiyaku Co., Ltd. INHIBITORS OF α4β1MEDIATED CELL ADHESION
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006431A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006435A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006437A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006434A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999010313A1 (en) * 1997-08-22 1999-03-04 F.Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
WO1999010312A1 (en) * 1997-08-22 1999-03-04 F. Hoffmann-La Roche Ag N-alkanoylphenylalanine derivatives
WO1999020606A2 (en) * 1997-10-23 1999-04-29 J. Uriach & Cia. S.A. Piperidines and piperazines as platelet aggregation inhibitors
WO1999023063A1 (en) * 1997-10-31 1999-05-14 Aventis Pharma Limited Substituted anilides
WO1999026945A1 (en) * 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS
JPH11158157A (ja) * 1997-09-18 1999-06-15 Hoechst Marion Roussel Deutsche Gmbh 新規なイミダゾリジン誘導体、その製造およびその使用ならびにそれを含有する医薬製剤
WO1999035163A1 (en) * 1998-01-08 1999-07-15 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999037618A1 (en) * 1998-01-27 1999-07-29 Celltech Therapeutics Limited Phenylalanine derivatives useful as pharmaceutical agents
JP2001089448A (ja) * 1999-09-24 2001-04-03 Yamanouchi Pharmaceut Co Ltd アミド誘導体
JP2002504534A (ja) * 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド α４インテグリンの阻害剤としてのフェニルアラニン誘導体
JP2002518491A (ja) * 1998-06-23 2002-06-25 ファルマシア・アンド・アップジョン・カンパニー α４β１媒介細胞接着のインヒビター
JP2002527416A (ja) * 1998-10-13 2002-08-27 エフ．ホフマン−ラ ロシュ アーゲー ジアミノプロピオン酸誘導体
JP2002537283A (ja) * 1999-02-18 2002-11-05 エフ．ホフマン−ラ ロシュ アーゲー フェニルアラニノール誘導体
JP2003524614A (ja) * 1998-12-22 2003-08-19 田辺製薬株式会社 α４β１媒介細胞接着のインヒビター
JP2003527306A (ja) * 1998-07-27 2003-09-16 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血栓症障害の処置のためのトリアゾロピリジン

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1149971B (it) 1979-06-11 1986-12-10 Syntex Inc Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en) 1985-01-23 1988-02-16 Abbott Laboratories Functionalized peptidylaminoalcohols
US4826815A (en) 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
DK163689A (da) 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
ATE75730T1 (de) 1988-07-21 1992-05-15 Pfizer Verfahren zur herstellung substituierter guanylthioharnstoffe.
US4908360A (en) 1988-11-14 1990-03-13 Hoechst-Roussel Pharmaceuticals Inc. 1-aminoalkyl-3-oxysubstituted-4-aryl-1,3,4,5-tetrahydro-2H-1,3-benzodiazepine-2-ones
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
DE69024230T2 (de) 1989-12-22 1996-05-02 Commw Scient Ind Res Org An fette gebundene aminosäuren, peptide oder deren derivate
CA2043741C (en) 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
CA2110387A1 (en) 1991-06-11 1992-12-23 Antonin R. Defougerolles Intercellular adhesion molecule-3 and its binding ligands
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
JPH07503944A (ja) 1991-11-22 1995-04-27 イエダ　リサーチ　アンド　デベロツプメント　カンパニー　リミテツド Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物
AU3420693A (en) 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de) 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en) 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
EP0677060A1 (en) 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
US5922755A (en) 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
JP2000516596A (ja) 1996-07-25 2000-12-12 バイオジェン，インコーポレイテッド 細胞接着インヒビター
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
CA2291708A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
ATE318841T1 (de) 1997-05-29 2006-03-15 Merck & Co Inc Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
IL133641A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999026923A1 (en) 1997-11-20 1999-06-03 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en) 1997-11-21 1999-06-03 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
ES2221227T3 (es) * 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
US6645939B1 (en) * 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
CA2325986A1 (en) * 1998-03-27 1999-10-07 Genentech, Inc. Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
DK1082302T3 (da) 1998-05-28 2004-04-26 Biogen Inc En VLA-4-inhibitor: oMePUPA-V
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
ES2270868T3 (es) * 1999-08-13 2007-04-16 Biogen Idec Ma Inc. Inhibidores de la adhesion celular.
US7196112B2 (en) * 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003094A1 (en) * 1995-07-11 1997-01-30 Biogen, Inc. Cell adhesion inhibitors
WO1997023480A1 (en) * 1995-12-22 1997-07-03 The Du Pont Merck Pharmaceutical Company Novel integrin receptor antagonists
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1997048395A1 (en) * 1996-06-19 1997-12-24 Du Pont Pharmaceuticals Company Iontophoretic delivery of integrin inhibitors
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
WO1998058902A1 (en) * 1997-06-23 1998-12-30 Tanabe Seiyaku Co., Ltd. INHIBITORS OF α4β1MEDIATED CELL ADHESION
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006431A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006435A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006437A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006434A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999010312A1 (en) * 1997-08-22 1999-03-04 F. Hoffmann-La Roche Ag N-alkanoylphenylalanine derivatives
WO1999010313A1 (en) * 1997-08-22 1999-03-04 F.Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
JPH11158157A (ja) * 1997-09-18 1999-06-15 Hoechst Marion Roussel Deutsche Gmbh 新規なイミダゾリジン誘導体、その製造およびその使用ならびにそれを含有する医薬製剤
WO1999020606A2 (en) * 1997-10-23 1999-04-29 J. Uriach & Cia. S.A. Piperidines and piperazines as platelet aggregation inhibitors
WO1999023063A1 (en) * 1997-10-31 1999-05-14 Aventis Pharma Limited Substituted anilides
WO1999026945A1 (en) * 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS
WO1999035163A1 (en) * 1998-01-08 1999-07-15 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999037618A1 (en) * 1998-01-27 1999-07-29 Celltech Therapeutics Limited Phenylalanine derivatives useful as pharmaceutical agents
JP2002504534A (ja) * 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド α４インテグリンの阻害剤としてのフェニルアラニン誘導体
JP2002518491A (ja) * 1998-06-23 2002-06-25 ファルマシア・アンド・アップジョン・カンパニー α４β１媒介細胞接着のインヒビター
JP2003527306A (ja) * 1998-07-27 2003-09-16 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血栓症障害の処置のためのトリアゾロピリジン
JP2002527416A (ja) * 1998-10-13 2002-08-27 エフ．ホフマン−ラ ロシュ アーゲー ジアミノプロピオン酸誘導体
JP2003524614A (ja) * 1998-12-22 2003-08-19 田辺製薬株式会社 α４β１媒介細胞接着のインヒビター
JP2002537283A (ja) * 1999-02-18 2002-11-05 エフ．ホフマン−ラ ロシュ アーゲー フェニルアラニノール誘導体
JP2001089448A (ja) * 1999-09-24 2001-04-03 Yamanouchi Pharmaceut Co Ltd アミド誘導体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002201168A (ja) * 2000-12-28 2002-07-16 Kaken Pharmaceut Co Ltd シクロヘキサン誘導体
JP2007518825A (ja) * 2004-01-23 2007-07-12 イーラン ファーマスーティカルズ、インコーポレイテッド 複素環式アルキルカルボキサミドプロパノン酸類のポリエチレングリコール抱合体類
JP2008505927A (ja) * 2004-07-08 2008-02-28 イーラン ファーマスーティカルズ、インコーポレイテッド ポリマー部分を含む多価ｖｌａ−４拮抗薬

Also Published As

Publication number Publication date
DE60031577T2 (de) 2007-08-23
HK1051500A1 (en) 2003-08-08
CZ2002518A3 (cs) 2002-05-15
BG65755B1 (bg) 2009-10-30
IL148014A (en) 2008-12-29
US7034043B2 (en) 2006-04-25
NZ517011A (en) 2004-02-27
KR100720907B1 (ko) 2007-05-25
EE200200070A (et) 2003-04-15
US20060166961A1 (en) 2006-07-27
HUP0202469A2 (hu) 2002-11-28
SK287075B6 (sk) 2009-11-05
MXPA02001449A (es) 2002-07-02
NO20020725L (no) 2002-04-08
CY1105912T1 (el) 2011-04-06
AU780610B2 (en) 2005-04-07
EP1741428A3 (en) 2007-05-09
ATE343383T1 (de) 2006-11-15
CA2380817A1 (en) 2001-02-22
YU9802A (sh) 2004-11-25
RS50470B (sr) 2010-03-02
EP1265606B9 (en) 2007-02-28
BR0013248A (pt) 2002-07-23
HUP0202469A3 (en) 2004-06-28
EP1265606B1 (en) 2006-10-25
DK1265606T3 (da) 2007-02-12
DE60031577D1 (de) 2006-12-07
EP1265606A4 (en) 2002-12-18
AU7058600A (en) 2001-03-13
EA005578B1 (ru) 2005-04-28
NO324044B1 (no) 2007-07-30
EA200200253A1 (ru) 2002-08-29
IS6257A (is) 2002-01-31
US6630503B1 (en) 2003-10-07
CN1377268A (zh) 2002-10-30
UA75581C2 (en) 2006-05-15
ES2270868T3 (es) 2007-04-16
EP1265606A1 (en) 2002-12-18
NO20020725D0 (no) 2002-02-13
BG106510A (bg) 2002-10-31
KR20020019973A (ko) 2002-03-13
PL354063A1 (en) 2003-12-15
IL148014A0 (en) 2002-09-12
GEP20063956B (en) 2006-11-10
GEP20053477B (en) 2005-03-25
US20040132809A1 (en) 2004-07-08
PT1265606E (pt) 2007-01-31
SK2152002A3 (en) 2002-07-02
EP1741428A2 (en) 2007-01-10
ZA200201158B (en) 2003-07-30
WO2001012186A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
KR100720907B1 (ko) 세포 유착 억제제
KR100637110B1 (ko) 세포 유착 억제제
JP2001524465A (ja) 細胞接着阻害剤としての置換β−アラニン誘導体
CZ20004425A3 (en) Compounds inhibiting cell adhesion and pharmaceutical preparation in which they are comprised
US7196112B2 (en) Cell adhesion inhibitors
KR20010034317A (ko) Ｖｌａ-4 길항제
US6686350B1 (en) Cell adhesion inhibitors
HK1099708A (en) Cell adhesion inhibitors
HK1051500B (en) Cell adhesion inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101116